PE20090968A1 - Compuestos para inhibir la actividad de ksp kinesina - Google Patents

Compuestos para inhibir la actividad de ksp kinesina

Info

Publication number
PE20090968A1
PE20090968A1 PE2008001777A PE2008001777A PE20090968A1 PE 20090968 A1 PE20090968 A1 PE 20090968A1 PE 2008001777 A PE2008001777 A PE 2008001777A PE 2008001777 A PE2008001777 A PE 2008001777A PE 20090968 A1 PE20090968 A1 PE 20090968A1
Authority
PE
Peru
Prior art keywords
alkyl
ksp
compounds
cycloalkyl
alkenyl
Prior art date
Application number
PE2008001777A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalalnthi Dilrukshi Vitharana
Angie R Angeles
Jr Gerald W Shipps
Xiaohua Huang
Cliff C Cheng
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40254344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090968(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090968A1 publication Critical patent/PE20090968A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE p ES 0-4; ANILLO A ES HETEROCICLOALQUENILO DE 4-8 MIEMBROS; E ES -O-, -S(O)-, NH, -CH2-, ENTRE OTROS; ANILLO B ES DE PREFERENCIA BENZO SUSTITUIDO O NO, TIOFENILO SUSTITUIDO O NO, ENTRE OTROS; R1 ES ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R2 ES ARILO, -C(O)ALQUILO, COCH3, CICLOALQUILO, ENTRE OTROS; R27 ES H, ALQUILO, ALQUENILO, ARILO, CICLOALQUENILO, ENTRE OTROS; R28 ES H ,ALQUILO, ALQUENILO, HETEROALQUENILO, CICLOALQUILO, ENTRE OTROS; R3 ES ALQUILO, ALQUENILO, HETEROALQUINILO, HETEROCICLOALQUILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES A. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINESINA DEL HUSO (KSP) UTILES EN EL TRATAMIENTO DE CANCER
PE2008001777A 2007-11-09 2008-10-16 Compuestos para inhibir la actividad de ksp kinesina PE20090968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98679907P 2007-11-09 2007-11-09

Publications (1)

Publication Number Publication Date
PE20090968A1 true PE20090968A1 (es) 2009-07-13

Family

ID=40254344

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001777A PE20090968A1 (es) 2007-11-09 2008-10-16 Compuestos para inhibir la actividad de ksp kinesina

Country Status (14)

Country Link
EP (1) EP2215064A1 (es)
JP (1) JP2011503076A (es)
KR (1) KR20100075508A (es)
CN (1) CN101952255A (es)
AR (1) AR068889A1 (es)
AU (1) AU2008325025A1 (es)
CA (1) CA2702990A1 (es)
CL (1) CL2008003062A1 (es)
IL (1) IL205181A0 (es)
MX (1) MX2010004314A (es)
PE (1) PE20090968A1 (es)
TW (1) TW200922559A (es)
WO (1) WO2009061596A1 (es)
ZA (1) ZA201002700B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5455915B2 (ja) * 2007-10-19 2014-03-26 メルク・シャープ・アンド・ドーム・コーポレーション Ｋｓｐキネシン活性を阻害するためのスピロ縮合した１，３，４−チアジアゾール誘導体
DE102008001932A1 (de) * 2008-05-21 2009-11-26 Bayer Cropscience Ag Substiuierte Spiroisoxazoline
CA3175724C (en) * 2014-03-20 2024-01-09 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5336470B2 (es) * 1971-08-09 1978-10-03
AU2003249597B2 (en) * 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101155583B (zh) * 2005-04-07 2011-01-19 默沙东公司 有丝分裂驱动蛋白的抑制剂

Also Published As

Publication number Publication date
CN101952255A (zh) 2011-01-19
KR20100075508A (ko) 2010-07-02
CA2702990A1 (en) 2009-05-14
AR068889A1 (es) 2009-12-16
JP2011503076A (ja) 2011-01-27
AU2008325025A1 (en) 2009-05-14
IL205181A0 (en) 2010-11-30
CL2008003062A1 (es) 2010-02-19
WO2009061596A1 (en) 2009-05-14
EP2215064A1 (en) 2010-08-11
ZA201002700B (en) 2010-12-29
MX2010004314A (es) 2010-04-30
TW200922559A (en) 2009-06-01

Similar Documents

Publication Publication Date Title
PE20160122A1 (es) Compuestos nobles y composiciones para la inhibicion de fasn
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20070321A1 (es) Compuestos heterociclicos como inhibidores de proteasas
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20200724A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
GT200500225A (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
ECSP11011244A (es) Nuevos herbicidas.
GT200300285A (es) Nuevos enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico
MX2011010449A (es) Derivados de oxadiazol.
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
ECSP11010880A (es) Compuestos orgánicos
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
UY31072A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
ECSP099817A (es) Procesos para la preparacion de pirazoles
MX2015008993A (es) Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina.
CO6700837A2 (es) Proceso de elaboración para derivados de prrimidina
MA35086B1 (fr) Compose de triazolopyridine
UY28700A1 (es) Compuestos
DOP2010000022A (es) Derivados de pirimidina 934

Legal Events

Date Code Title Description
FD Application declared void or lapsed